TanakaM.Therapeutic drug monitoring of natalizumab. Mult Scler2019; 25: 1689–1690.
2.
SehrTProschmannUThomasK, et al. New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. J Neuroinflammation2016; 13(1): 164.
3.
Van KempenZIRispensTKillesteinJ.The majority of patients have high natalizumab concentrations at time of re-dosing. Mult Scler2018; 24(6): 822–823.
4.
TanakaMKinoshitaMFoleyJF, et al. Body weight-based natalizumab treatment in adult patients with multiple sclerosis. J Neurol2015; 262(3): 781–782.
5.
O’ConnorP.Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. Expert Opin Biol Ther2007; 7(1): 123–136.
